CEL-SCI (CVM) Presents Data Showing LEAPS Vaccine is Successful in Reducing Rheumatoid Arthritis Index Score in a Second Animal Model
5/6/2013 10:10:21 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today announced results from a recently completed efficacy study in a second animal model of rheumatoid arthritis (RA) using the LEAPS technology (LEAPS), which demonstrates that LEAPS has the potential for use as a therapeutic vaccine to treat different types of RA, each of which possesses different disease characteristics. The study was conducted in collaboration with Dr. Tibor Glant’s research team at Rush University Medical Center. Dr. Glant holds the “Jorge O. Galante, MD” Endowed Chair Professorship in Orthopedic Surgery at Rush. The data was presented on May 4th by Daniel Zimmerman, Ph.D., CEL-SCI’s Senior Vice President, Cellular Immunology, at the symposium on “Therapeutic Approaches to Autoimmunity” during the American Association of Immunologists (AAI) 100th annual meeting in Honolulu, HI.
Help employers find you! Check out all the jobs and post your resume.
comments powered by